Anesthetic Implications of a 10-Year-Old Posted for Adenotonsillectomy

1. PREOPERATIVE EVALUATION

Indications (Establish Which)

• Recurrent tonsillitis - primarily infectious indication
• Obstructive symptoms / OSA - most common reason in this age group; has major anesthetic implications
• Peritonsillar abscess, tonsillar hypertrophy

Key Preoperative Assessment

• Snoring, witnessed apneas, mouth breathing, restless sleep, daytime somnolence
• These suggest obstructive sleep apnea (OSA) - a critical risk modifier
• Despite only mild-to-moderate tonsillar enlargement on examination, children with OSA have true upper airway obstruction. Do not underestimate severity based on tonsillar size alone. (Barash, Clinical Anesthesia 9e)

• Gold standard is polysomnography (PSG); yields apnea-hypopnea index (AHI)
• OSA is classified as severe if AHI > 10 and O2 saturation nadir < 80%
• In practice, most children proceed without formal PSG; clinical scoring tools and overnight oximetry are used
• The AAP recommends PSG when alternative screening is inconclusive; AAO-HNS recommends PSG when tonsillar size and symptoms are discordant

• Tonsillar size (Brodsky grading), nasal obstruction, facial morphology
• Body weight and BMI - obesity independently increases OSA risk and opioid sensitivity
• Craniofacial abnormalities (small mandible, large tongue, thick neck) increase obstruction risk under anesthesia

• Full blood count (assess for chronic hypoxia-related polycythemia, coagulation baseline)
• Coagulation studies if personal/family bleeding history
• ECG/ECHO if suspicion of right heart strain (cor pulmonale from chronic hypoxia)

• Down syndrome, craniofacial syndromes - higher OSA risk and difficult airway
• Bleeding diathesis - relevant to post-tonsillectomy hemorrhage risk
• Recent URTI - elective surgery should be deferred for 4-6 weeks after acute infection

2. PREMEDICATION

• Use sparingly - sedative premedication should be avoided in children with OSA, severe intermittent obstruction, or very large tonsils (risk of airway compromise)
• Midazolam oral premedication (0.5 mg/kg) may be used in non-OSA anxious children
• An antisialagogue (atropine 0.02 mg/kg IV or glycopyrrolate) may be given to minimize secretions in the operative field
• Parental presence during mask induction may help in anxious, unpremedicated children

3. INDUCTION OF ANESTHESIA

• Inhalational induction with sevoflurane + O2 ± N2O is standard for this age
• Parental presence during mask induction is helpful for the anxious child
• IV induction with propofol is an alternative once IV access is established

• Tracheal intubation under deep inhalational anesthesia or with a short-acting non-depolarizing muscle relaxant (atracurium, rocuronium)
• Succinylcholine reserved for rapid sequence situations
• Many clinicians eliminate NMB and use propofol to deepen anesthesia instead

4. AIRWAY MANAGEMENT

Preformed RAE Endotracheal Tube

• South-facing preformed (nasal or oral RAE) - keeps the circuit away from the surgical field
• Cuffed ETT preferred - protects the airway from blood entering the trachea during surgery
• If cuffed ETT used: careful attention to cuff inflation pressure to avoid post-extubation subglottic edema/croup
• Pack the supraglottic area with petroleum gauze to prevent blood from entering the trachea if uncuffed tube used

Flexible (Reinforced) LMA

• Growing trend; the flexible/armored LMA fits under the mouth gag without compression or dislodgment - the wide, rigid standard LMA does not fit under the mouth gag
• Advantages: decreased post-op stridor, reduced laryngospasm, better immediate post-op O2 saturation compared to ETT
• Disadvantages: risk of airway fire if electrocautery contacts the LMA cuff; does not provide same airway protection as ETT
• Insertion requires same depth as for laryngoscopy; avoid excessive peak inspiratory pressure
• Tonsillar enlargement can impede LMA insertion - maneuvers include head extension, lateral insertion, anterior tongue displacement
• An orogastric tube may be passed through the suction port post-operatively to decompress the stomach

5. MAINTENANCE OF ANESTHESIA

• Either volatile (sevoflurane, desflurane, isoflurane) or total intravenous anesthesia (TIVA) with propofol infusion can be used
• Monitoring: ECG, NIBP, pulse oximetry, precordial stethoscope, end-tidal CO2 capnography
• Positioning: supine with neck extended (shoulder roll), head ring; Boyle-Davis mouth gag and Doughty tongue plate used by surgeons - verify airway integrity after gag insertion

6. ANALGESIA (Multimodal Approach)

Codeine - ABSOLUTELY CONTRAINDICATED

• FDA black box warning and AAO-HNS guidelines strictly contraindicate codeine in children post-tonsillectomy
• A subset of children are ultra-rapid CYP2D6 metabolizers - codeine is rapidly converted to morphine at toxic levels
• Combined with OSA-induced opioid sensitivity, this can be fatal
• Multiple case reports of deaths following tonsillectomy with codeine in children with OSA

7. OSA-SPECIFIC CONSIDERATIONS (Critical for This Case)

• Non-OSA child: may be discharged after standard recovery (some centers require ≥4 hours observation)
• Known/suspected OSA: observe at least 4 hours post-op; if any obstructive events, observe additional 7 hours
• Severe OSA (AHI > 10, SpO2 nadir < 80%) or OSA with comorbidities (obesity, Down syndrome, craniofacial abnormality, age < 3 years): admit overnight
• Death and neurological injury have been reported after tonsillectomy in children at risk for OSA who were not adequately monitored post-operatively

8. EXTUBATION/LMA REMOVAL

• Child is fully awake and able to clear secretions/blood from oropharynx before device removal
• Preferred in OSA patients and those with full stomach risk
• Risk: coughing/bucking on tube may precipitate bleeding from tonsillar fossa

• Removes device while still under anesthesia - avoids coughing and associated bleeding
• Risk: airway obstruction after device removal
• Requires: immediate availability of skilled personnel and equipment to manage obstruction; suitable only in specific clinical contexts

9. POSTOPERATIVE COMPLICATIONS

PONV

• Incidence 30-65% after tonsillectomy - among the highest of any procedure
• Causes: blood in stomach (irritant), gag reflex stimulation, gastric distension from air
• Management: orogastric tube to decompress stomach; ondansetron + dexamethasone combination is highly effective
• Recent meta-analysis (PMID 39992376, 2025) confirms ondansetron reduces PONV in children post-adenotonsillectomy

Post-tonsillectomy Hemorrhage

• Primary (< 24 hours) or secondary (5-10 days post-op, reactionary)
• Minor bleeding: conservative management
• Active/significant bleeding: return to theatre
• Anesthetic considerations for bleeding tonsil:
  • Patient may have swallowed large volumes of blood (unappreciated hypovolemia) - full stomach precaution is mandatory
  • Active bleeding + swelling = potentially difficult laryngoscopy
  • Treat as RSI (rapid sequence induction) with volume resuscitation before induction
  • Awake preoxygenation in left lateral position or head-down to prevent aspiration
  • Have senior anesthetist and full difficult airway equipment ready

Laryngospasm

• Risk: at induction, on emergence, and from blood/secretions in the airway
• Most common cause of respiratory arrest in pediatric anesthesia
• Managed with: CPAP, deepening anesthesia, succinylcholine (0.1-0.2 mg/kg IV or 4 mg/kg IM)

Post-extubation Croup

• From cuffed ETT irritation - prevent by using appropriately sized tube and monitoring cuff pressure
• Treated with nebulized racemic epinephrine, dexamethasone, humidified O2

Emergence Agitation

• Common in this age group, especially with volatile anesthetics
• Dexmedetomidine intraoperatively significantly reduces incidence

10. SUMMARY TABLE

• Barash, Cullen, and Stoelting's Clinical Anesthesia, 9e - Chapter on Anesthesia for Pediatric ENT Surgery
• Miller's Anesthesia, 10e - Tonsillectomy and Adenoidectomy section
• Morgan & Mikhail's Clinical Anesthesiology, 7e - Pediatric Anesthesia chapter
• Recent evidence: dexmedetomidine for emergence agitation (PMID 41469848, 2025 meta-analysis); ondansetron for PONV (PMID 39992376, 2025 meta-analysis)